What 4 Analyst Ratings Have To Say About Taysha Gene Therapies
Portfolio Pulse from Benzinga Insights
Taysha Gene Therapies (NASDAQ:TSHA) has received four bullish ratings from analysts in the last quarter. The average 12-month price target for the company, according to these analysts, is $4.75, with a high of $6.00 and a low of $2.00. This average has increased by 58.33% from the previous average price target of $3.00.
June 30, 2023 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies has received positive ratings from analysts, which could potentially boost investor confidence and positively impact the stock price in the short term.
Analyst ratings often influence investor sentiment and can impact stock prices. In this case, Taysha Gene Therapies has received four bullish ratings, which indicates a positive outlook for the company. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100